Integrated analysis of expression profiling data identifies three genes in correlation with poor prognosis of triple-negative breast cancer

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 2025-2033

  Zhang, Cheng ^a   Han, Yong ^a   Huang, Hao ^a   Min, Li ^a   Qu, Like ^a   Shou, Chengchao ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Expression profiling data; Prognosis correlated genes; Triple negative breast cancer

Indexed keywords

ADULT; ARTICLE; BIOINFORMATICS; BIRC5 GENE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CENPA GENE; COHORT ANALYSIS; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; FAM64A GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC CORRELATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETICS; PATHOLOGY; PROGNOSIS; CANCER SURVIVAL; DATA BASE; GENETIC ASSOCIATION; MEDICAL INFORMATION SYSTEM;

BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR MARKER; CENTROMERE PROTEIN A; FAMILY WITH SEQUENCE SIMILARITY 64 MEMBER A; MEMBRANE PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

DATABASES, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899505137     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2352     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434, 2007.
3. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF and Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32, 2007.
4. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005.
5. Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med 363: 1938-1948, 2010.
6. Mahamodhossen YA, Liu W and Rong-Rong Z: Triple-negative breast cancer: new perspectives for novel therapies. Med Oncol 30: 653, 2013.
7. Cleator S, Heller W and Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol 8: 235-244, 2007.
8. Schneider BP, Winer EP, Foulkes WD, et al: Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14: 8010-8018, 2008.
9. Bosch A, Eroles P, Zaragoza R, Viña JR and Lluch A: Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 36: 206-215, 2010.
10. Balko JM, Cook RS, Vaught DB, et al: Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 18: 1052-1059, 2012.
11. Ur-Rehman S, Gao Q, Mitsopoulos C and Zvelebil M: ROCK: a resource for integrative breast cancer data analysis. Breast Cancer Res Treat 139: 907-921, 2013.
12. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002.
13. Chin K, DeVries S, Fridlyand J, et al: Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10: 529-541, 2006.
14. Butte A: The use and analysis of microarray data. Nat Rev Drug Discov 1: 951-960, 2002.
15. Han Y, Huang H, Xiao Z, et al: Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer. PLoS One 7: e52745, 2012.
16. Konstantinopoulos PA, Cannistra SA, Fountzilas H, et al: Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer. PLoS One 6: e18202, 2011.
17. Richardson AL, Wang ZC, De Nicolo A, et al: X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9: 121-132, 2006.
18. Brown MP, Grundy WN, Lin D, et al: Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc Natl Acad Sci USA 97: 262-267, 2000.
19. Perreard L, Fan C, Quackenbush JF, et al: Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 8: R23, 2006.
20. Hu Z, Fan C, Oh DS, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96, 2006.
21. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U and Harbeck N: Triple-negative breast cancer - current status and future directions. Ann Oncol 20: 1913-1927, 2009.
22. Rouzier R, Perou CM, Symmans WF, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685, 2005.
23. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002.
24. Hinnis AR, Luckett JC and Walker RA: Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer 96: 639-645, 2007.
25. Span PN, Tjan-Heijnen VC, Heuvel JJ, de Kok JB, Foekens JA and Sweep FC: Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer? Clin Chem 52: 1693-1700, 2006.
26. Islam A, Kageyama H, Takada N, et al: High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19: 617-623, 2000.
27. Regnier V, Vagnarelli P, Fukagawa T, et al: CENP-A is required for accurate chromosome segregation and sustained kinetochore association of BubR1. Mol Cell Biol 25: 3967-3981, 2005.
28. Amato A, Schillaci T, Lentini L and Di Leonardo A: CENPA overexpression promotes genome instability in pRb-depleted human cells. Mol Cancer 8: 119, 2009.
29. Archangelo LF, Greif PA, Maucuer A, et al: The CATS (FAM64A) protein is a substrate of the Kinase Interacting Stathmin (KIS). Biochim Biophys Acta 1833: 1269-1279, 2013.
30. Takagi K, Miki Y, Shibahara Y, et al: BUB1 immunolocalization in breast carcinoma: its nuclear localization as a potent prognostic factor of the patients. Horm Cancer 4: 92-102, 2013.
31. Li L, Xu DB, Zhao XL and Hao TY: Combination analysis of Bub1 and Mad2 expression in endometrial cancer: act as a prognostic factor in endometrial cancer. Arch Gynecol Obstet 288: 155-165, 2013.
32. Hegyi K and Mehes G: Mitotic failures in cancer: Aurora B kinase and its potential role in the development of aneuploidy. Pathol Oncol Res 18: 761-769, 2012.
33. Takeshita M, Koga T, Takayama K, et al: Aurora-B overexpression is correlated with aneuploidy and poor prognosis in non-small cell lung cancer. Lung Cancer 80: 85-90, 2013.
34. Tchatchou S, Wirtenberger M, Hemminki K, et al: Aurora kinases A and B and familial breast cancer risk. Cancer Lett 247: 266-272, 2007.